✓ Clinically Audited: August 2026 • OncoGuides Medical Advisory Board

Colorectal Cancer: Staging, MSI/dMMR, RAS/BRAF Mutations & Systemic Regimens

Evidence-based management of colon and rectal adenocarcinoma across Stage I through metastatic disease.

Anatomical Site / System Colon and Rectum (Large Bowel Mucosa)

Staging System AJCC TNM 8th Edition

Primary Biomarkers MMR (MLH1, MSH2, MSH6, PMS2), MSI (PCR/NGS), KRAS, NRAS, BRAF V600E, HER2, DPYD

Standard Guidelines NCCN, ASCO, ESMO 2026 Consensus

1. Overview & Pathophysiology

Colorectal cancer (CRC) develops predominantly through the adenoma-carcinoma sequence via chromosomal instability (CIN) or the microsatellite instability (MSI) pathway. In 2026, anatomical tumor sidedness (Right-sided: cecum to hepatic flexure vs Left-sided: splenic flexure to rectum) and molecular status (RAS/BRAF wild-type vs mutant, and dMMR/MSI-H vs pMMR/MSS) dictate systemic regimen and biologic selection.

2. Molecular Subtypes & Biomarker Profiling

Critical predictive biomarkers in colorectal adenocarcinoma:

Mismatch Repair (dMMR) / Microsatellite Instability (MSI-H): Found in ~15% of stage II/III and ~5% of metastatic CRC. Predicts exceptional responsiveness to immune checkpoint inhibitors (Pembrolizumab, Nivolumab+Ipilimumab) and lack of benefit from adjuvant 5-FU monotherapy in stage II.
KRAS & NRAS (Exons 2, 3, 4): Mutations in codons 12, 13, 59, 61, 117, 146 confer constitutive downstream MAPK activation and predict resistance to anti-EGFR monoclonal antibodies (Cetuximab, Panitumumab).
BRAF V600E: Identifies an aggressive molecular subset (~10%). Directs targeted therapy with Encorafenib + Cetuximab in second-line metastatic CRC (BEACON CRC trial).
DPYD Gene Polymorphisms: Dihydro-pyrimidine dehydrogenase deficiency testing prevents life-threatening 5-FU/Capecitabine toxicities.

3. Standard-of-Care Treatment Protocols (NCCN/ASCO 2026)

Stage / Sidedness / Biology	Standard First-Line Protocol	Key Clinical Consideration
Stage III Colon (High-risk T4 or N2)	FOLFOX (Oxaliplatin, Leucovorin, 5-FU) or CAPOX x 6 months	IDEA trial supports 3 months CAPOX for low-risk T1-3N1 to reduce neuropathy
mCRC: MSI-H / dMMR	Pembrolizumab 200 mg q3w or Nivolumab + Ipilimumab	Substantially superior PFS and OS compared to traditional chemotherapy
mCRC: Left-Sided, RAS/BRAF WT	FOLFOX or FOLFIRI + Panitumumab or Cetuximab	Anti-EGFR biologic improves response rate and overall survival in left-sided tumors
mCRC: Right-Sided or RAS Mutant	FOLFOX or FOLFIRI or FOLFOXIRI + Bevacizumab	Anti-VEGF angiogenesis inhibition preferred over anti-EGFR therapy

4. Supportive Oncology & Organ Comorbidities

Multidisciplinary Supportive Care Links:

Managing therapy-induced organ toxicities is essential for maintaining dose intensity and overall survival:

Cardiotoxicity & LVEF Monitoring: CardioOncoGuides (Anthracycline & HER2-induced cardiomyopathy).
Renal Function & Cisplatin AKI: NephroOncoGuides (GFR calculators, TLS & hydration protocols).
Pulmonary Toxicity & Pneumonitis: PulmonaryOncoGuides (ICI pneumonitis steroid tapers & Bleomycin DLCO).
Cutaneous Toxicities & EGFR Rash: OncoDermatologyGuides (SCORTEN calculators, doxycycline tapers & scalp cooling).
Chemotherapy Neuropathy (CIPN): NeuroOncoGuides (Duloxetine titration & cryotherapy).
Cancer-Related Lymphedema: LymphedemaOncoGuides (Complete Decongestive Therapy CDT).
Fertility Preservation: OncoFertilityGuides (Oocyte/sperm cryopreservation & GnRH-a).
Psychosocial Support: PsychoOncoGuides (Distress Thermometer & free psychotherapy grants).

5. Patient & Caregiver Frequently Asked Questions

Why does tumor sidedness matter in metastatic colon cancer?

Right-sided colon cancers (arising from the embryologic midgut) exhibit distinct gene expression profiles with higher rates of KRAS/BRAF mutations and poor prognosis. Left-sided cancers (hindgut) with wild-type RAS/BRAF derive significant survival benefit from anti-EGFR therapies (Cetuximab/Panitumumab) when added to first-line chemotherapy.

What is the recommended management for oxaliplatin-induced cold sensitivity and neuropathy?

Oxaliplatin causes acute cold-induced paresthesias and cumulative sensory peripheral neuropathy. Patients should avoid cold beverages, wear warm gloves, and consult NeuroOncoGuides for duloxetine protocols.

6. Primary Evidence & Guideline Citations

Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2026. J Natl Compr Canc Netw. PMID: 34144521.
Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer (KEYNOTE-177). N Engl J Med. 2020;383(23):2207-2218. PMID: 33264544.
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer (BEACON CRC). N Engl J Med. 2019;381(17):1632-1643. PMID: 31566309.